» Articles » PMID: 26175967

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma

Overview
Journal Front Oncol
Specialty Oncology
Date 2015 Jul 16
PMID 26175967
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric brain cancer with no effective therapy. Histological similarity of DIPG to supratentorial high-grade astrocytomas of adults has led to assumptions that these entities possess similar underlying molecular properties and therefore similar therapeutic responses to standard therapies. The failure of all clinical trials in the last 30 years to improve DIPG patient outcome has suggested otherwise. Recent studies employing next-generation sequencing and microarray technologies have provided a breadth of evidence highlighting the unique molecular genetics and epigenetics of this cancer, distinguishing it from both adult and pediatric cerebral high-grade astrocytomas. This review describes the most common molecular genetic and epigenetic signatures of DIPG in the context of molecular subgroups and histopathological diagnosis, including this tumor entity's unique mutational landscape, copy number alterations, and structural variants, as well as epigenetic changes on the global DNA and histone levels. The increased knowledge of DIPG biology and histopathology has opened doors to new diagnostic and therapeutic avenues.

Citing Articles

Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery.

Presswala Z, Acharya S, Shah S ADMET DMPK. 2024; 12(3):403-429.

PMID: 39091904 PMC: 11289511. DOI: 10.5599/admet.2214.


Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.

Weisbrod L, Thiraviyam A, Vengoji R, Shonka N, Jain M, Ho W Cancer Lett. 2024; 590:216876.

PMID: 38609002 PMC: 11231989. DOI: 10.1016/j.canlet.2024.216876.


Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.

Lulla R, Buxton A, Krailo M, Lazow M, Boue D, Leach J Neurooncol Adv. 2024; 6(1):vdae035.

PMID: 38596718 PMC: 11003537. DOI: 10.1093/noajnl/vdae035.


Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.

Chen Y, Khan A, Katsinas C, Michniewicz F, Goldberg J, Franshaw L Neurooncol Adv. 2024; 6(1):vdae029.

PMID: 38550394 PMC: 10976909. DOI: 10.1093/noajnl/vdae029.


ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T J Clin Oncol. 2024; 42(13):1542-1552.

PMID: 38335473 PMC: 11095894. DOI: 10.1200/JCO.23.01134.


References
1.
Veldhuijzen van Zanten S, Jansen M, Sanchez Aliaga E, van Vuurden D, Vandertop W, Kaspers G . A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther. 2014; 15(2):157-64. DOI: 10.1586/14737140.2015.974563. View

2.
Wright W, Piatyszek M, Rainey W, Byrd W, Shay J . Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996; 18(2):173-9. DOI: 10.1002/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3. View

3.
Rood B, MacDonald T . Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol. 2005; 75(3):267-72. DOI: 10.1007/s11060-005-6749-5. View

4.
Harley C, Futcher A, Greider C . Telomeres shorten during ageing of human fibroblasts. Nature. 1990; 345(6274):458-60. DOI: 10.1038/345458a0. View

5.
Paugh B, Zhu X, Qu C, Endersby R, Diaz A, Zhang J . Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 2013; 73(20):6219-29. PMC: 3800209. DOI: 10.1158/0008-5472.CAN-13-1491. View